TAVR or Surgery for Intermediate-Risk Patients? (GARY Registry)

New findings from the GARY (German Aortic Valve Registry) registry show that intermediate-risk patients with severe aortic stenosis presented significantly higher mortality at 1 year when treated with transcatheter aortic valve replacement (TAVR) rather than with conventional surgery.

 

Results reflect everyday realities, which might include various bias tipping the scales towards one strategy or the other, and which could have contributed to the results.

 

The survival difference favoring surgery shown in the registry persisted even after propensity-score matching, but that does not rule out the presence of many other unadjusted confounding variables.

 

Almost 50,000 patients were enrolled in the GARY registry between January 2011 and December 2013, of whom 22.7% presented intermediate surgical risk (logistic EuroSCORE 10-20%).

 

Overall, 5997 patients who underwent TAVR or isolated valve surgery were included in the analysis.

 

Baseline differences between groups were striking, since patients who underwent TAVR showed higher surgical risk, presented greater age, worse heart failure, more prior myocardial infarction, more atrial fibrillation The most frequent reasons underlying the choice of TAVR over surgery were patient age and frailty.

 

Many of these factors might have affected the rate of all-cause mortality at a year: 8.9% for surgery vs. 16.6% for TAVR (p < 0.001).

 

The decision to choose one strategy over the other was made by a heart team in over 90% of patients, and it is clearly impossible to adjust for medical opinion.

 

Original title: Patients at Intermediate Surgical Risk Undergoing Isolated Interventional or Surgical Aortic Valve Replacement for Severe Symptomatic Aortic Valve Stenosis.

Presenter: Werner N.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....